Eric M. Dube - 04 Jan 2022 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
Chief Executive Officer, Director
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol
TVTX
Transactions as of
04 Jan 2022
Net transactions value
-$521,407
Form type
4
Filing time
06 Jan 2022, 15:03:07 UTC
Previous filing
17 Aug 2021
Next filing
26 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Sale $147,038 -4,832 -3.1% $30.43 152,083 04 Jan 2022 Direct F1
transaction TVTX Common Stock Sale $309,172 -10,361 -6.8% $29.84 141,722 05 Jan 2022 Direct F2, F3
transaction TVTX Common Stock Sale $65,197 -2,139 -1.5% $30.48 139,583 05 Jan 2022 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2 The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 to $30.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.38 to $30.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.